Parabilis Medicines’ Nasdaq IPO landed at $670 million, extending a record-breaking run of biotech public listings and signaling that investor appetite is returning to the sector’s highest-profile growth stories. The deal overtook Kailera Therapeutics’ prior $625 million benchmark earlier in the year and came amid other sizable listings, including Avalyn Pharma, Seaport Therapeutics, and Odyssey Therapeutics. The reporting attributes the surge to “dry-powder” capital accumulated during the post-pandemic funding gap, when venture and strategic investors slowed deployment despite having resources. It also points to improved downstream liquidity—acquisition activity and public-market openings—as key precursors for IPO rollouts. For operators, the development affects hiring, financing strategy, and competitive positioning—particularly for platform and tumor-focused companies seeking to convert clinical progress into permanent capital access.